Cingulate Inc., a company listed on the Nasdaq Capital Market, has announced an increase in the maximum aggregate offering price of its common stock under the At The Market Offering Agreement with H.C. Wainwright & Co. The increase, reported on August 19, 2024, raises the offering from $8,470,000 to $11,326,658, with a prospectus supplement filed for an additional $2,856,658 in shares. Prior to this, Cingulate Inc. had sold shares totaling $8,468,402.99 under the same agreement. Additionally, on August 15, 2024, Cingulate Inc. disclosed the issuance of a European patent for CTx-1301, a treatment for Attention Deficit Hyperactivity Disorder (ADHD), which will extend to up to 30 European territories, including the UK. The patent was granted on August 14, 2024, as EP Patent No. 3261625.

Cingulate Inc., a company listed on the Nasdaq Capital Market, has announced an increase in the maximum aggregate offering price of its common stock under the At The Market Offering Agreement with H.C. Wainwright & Co. The increase, reported on August 19, 2024, raises the offering from $8,470,000 to $11,326,658, with a prospectus supplement filed for an additional $2,856,658 in shares. Prior to this, Cingulate Inc. had sold shares totaling $8,468,402.99 under the same agreement. Additionally, on August 15, 2024, Cingulate Inc. disclosed the issuance of a European patent for CTx-1301, a treatment for Attention Deficit Hyperactivity Disorder (ADHD), which will extend to up to 30 European territories, including the UK. The patent was granted on August 14, 2024, as EP Patent No. 3261625.